Table 3.
Clinical outcome of transformed SCLC from LUAD with EP plus anlotinib.
Clinical efficacy | Number (%) |
---|---|
CR | 1 (10%) |
PR | 7 (70%) |
SD | 2 (20%) |
PD | 0 (0%) |
ORR (CR+PR) | 8 (80%) |
DCR (CR+PR+SD) | 10 (100%) |
CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; ORR, overall response rate; and DCR, disease control rate.